Spectroscopic diagnosis of chronic fatigue syndrome by visible and near-infrared spectroscopy in serum samples.
Sakudo, Akikazu, Kuratsune, Hirohiko, Kobayashi, Takanori et al. · Biochemical and biophysical research communications · 2006 · DOI
Quick Summary
Researchers used a special light-based scanning technique to analyze blood samples from ME/CFS patients and healthy people. The scans could correctly identify which samples came from ME/CFS patients about 93% of the time. This suggests that a simple blood test using this technology might one day help doctors diagnose ME/CFS objectively, rather than relying only on symptoms and other tests.
Why It Matters
ME/CFS currently lacks objective diagnostic biomarkers, forcing clinicians to rely on clinical criteria and exclusion of other conditions. A non-invasive blood-based spectroscopic test could improve diagnostic accuracy, reduce diagnostic delay, and potentially identify biochemical abnormalities underlying the disease. This work contributes to the growing body of evidence that ME/CFS has detectable biological signatures in blood.
Observed Findings
Vis-NIR spectra in the 600-1100 nm region showed measurable differences between ME/CFS and healthy serum samples
The SIMCA model correctly identified 100% (54/54) of healthy donor samples in masked validation
The SIMCA model correctly identified 93.3% (42/45) of ME/CFS patient samples in masked validation
Principal component analysis successfully separated the two groups spectroscopically
Inferred Conclusions
Vis-NIR spectroscopy combined with chemometric analysis can discriminate between ME/CFS patients and healthy individuals with high accuracy
This approach may serve as an objective diagnostic tool for ME/CFS if validated in larger, independent populations
Biochemical differences in serum exist between ME/CFS patients and controls that are detectable via spectroscopic methods
Remaining Questions
What specific biochemical compounds or molecular changes produce the observed spectral differences between groups?
Will this diagnostic accuracy hold in larger, more diverse populations and independent validation cohorts?
Can this method distinguish ME/CFS from other conditions with similar symptoms (e.g., depression, other chronic illnesses)?
What This Study Does Not Prove
This study does not prove that the observed spectral differences reflect the cause of ME/CFS or explain which biochemical components drive the discrimination. It does not establish whether spectral changes are disease-specific or could occur in other conditions. The study cannot be generalized beyond the specific populations tested without larger, independent validation cohorts.